Front Page

Researchers Patent Drug Treatment to Boost Protein Production in the Brain

As reported in Twin Cities Business on November 23rd, a team of researchers has patented a drug treatment that stimulates the production of progranulin (PGRN), a protein necessary in maintaining the health of the brain’s frontal and temporal lobes. Deficiencies of PGRN have been linked to both FTD and ALS. The researchers — led by the Mayo Clinic’s Rosa Rademakers, who received the Potamkin Prize earlier this year — also patented a benign virus designed to deliver the drug to the brain.

Emerging Treatments Could Apply to Multiple Forms of Dementia

Researchers are hard at work developing treatments for FTD, Alzheimer’s disease and other forms of dementia, writes Dr. Howard Fillit, executive director of the Alzheimer’s Drug Discovery Foundation (ADDF), in a Nov. 22 Huffington Post article. Dr. Fillit briefly explains numerous other forms of dementia in the article, explaining that many share the same physical causes (including rogue proteins in the brain, impaired blood flow, and neuroinflammation). He highlights several researchers currently investigating promising treatments that target these causes. Among them are Dr. Mari DeMarco of the University of British Columbia and Dr. Keith St. Lawrence of the Lawson Health Research Institute in Canada, both of whom received 2015 Drug Discovery Grants from AFTD and ADDF to support their research.

Mayo Clinic Researchers Patent Genetic FTD Test

Researchers have patented an innovative molecular test that can measure a genetic mutation linked to both FTD and ALS. Members of the Mayo Clinic’s Neurodegenerative Diseases Lab — led by Leonard Petrucelli, chairman of the neurology department at the clinic’s Florida location — received approval for the patent on September 20. The molecular test (also known as an immunoassay) is able to diagnose properties of the mutated gene C9ORF72, which causes the most common genetic forms of FTD and ALS. Dr. Petrucelli sits on the scientific advisory board of the FTD Biomarkers Initiative.

Neurology Now Features Actress Kimberly Williams-Paisley

Actress Kimberley Williams-Paisley, whose mother passed away from PPA, is featured in the cover story of the October/November issue of Neurology Now. Williams-Paisley wrote a book about her mother’s FTD journey, Where the Light Gets In, published earlier this year (AFTD discussed the book with her this past April.) In the Neurology Now article, Williams-Paisley discusses the challenges she and her family faced while caring for her mother, the regrets she still feels about her mom’s final years and the importance of FTD education and awareness. Read the entire article here.

AFTD’s Inaugural Hope Rising Benefit

Three members of the AFTD community, Donald Newhouse, AFTD Board member Kathy Newhouse Mele, and Daniel Hedaya, will host AFTD’s inaugural New York City benefit, Hope Rising. The evening will celebrate one of AFTD’s most generous supporters, David Zaslav, President and CEO of Discovery Communications, who will be honored with the Susan Newhouse & Si Newhouse Award of Hope. Paula Zahn will be hosting the evening, with a special performance by KellFor more details on the event, including the , and who will be in attendance, click

American Journalist and Newscaster, Paula Zahn will be hosting the event, and Tony Award Winning actress, Kelli O’Hara will be giving a special performance. For more details on the event, including who will be in attendance, click here.